This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,480,500.00 to The Trustees of Columbia University in the City of New York to develop a peptide-based drug delivery system targeting metastatic prostate cancer. The project will run from September 15, 2023 to September 14, 2026. The Department of Defense grant supports basic, applied, and advanced biomedical research with the goal of transforming healthcare for military Service Members and the public. Columbia University, a private university and non-profit organization, has extensive experience conducting biomedical research funded through federal contracts and grants from agencies like the Department of Defense and National Institutes of Health.